Pfizer Inc (PFE)
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Last price
- $29.21
- As of
Kresmion compiles this page from PFE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
PFIZER INC (PFE): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.
See the full PFE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PFE on one page. Preview it with sample data, then open it live with a free account.
Preview the PFE dossierActive signals for PFE
- highFDA_APPROVAL
FDA approves XELJANZ (PFIZER)
- highCONSENSUS_BUY
6 tracked funds increased PFE this 2026Q2, institutional consensus
- highFDA_APPROVAL
FDA approves ZAVZPRET (PFIZER)
- highFDA_APPROVAL
FDA approves CIBINQO (PFIZER)
- highCONSENSUS_SELL
3 tracked funds reduced PFE this 2026Q2, institutional consensus
FREE, NO ACCOUNT
Every signal on PFE, as it fires
You are seeing 5 of 237 signals recorded on PFE since 2026-05-02.
The five above landed across 4 days. The other 232 were recorded on 45 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PFE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 717081103 · 2026Q2 | $149.1M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 717081103 · 2026Q2 | $130.4M | 0.06% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 717081103 · 2026Q2 | $13.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 717081103 · 2026Q2 | $8M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 717081103 · 2026Q2 | $4.3M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PFE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PFE mentioned in Kresmion daily briefs
PFE against its peers
PFE's net margin of 12.4% ranks in the 50th percentile of 22 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.
| Metric | PFE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 62.6B USD | 6.2B USD | 84 | 21 |
| Gross margin | n/a | 70.1% | n/a | 10 |
| Operating margin | n/a | 10.5% | n/a | 16 |
| Net margin | 12.4% | 10.6% | 50 | 22 |
| Return on equity | 9.0% | 17.8% | 44 | 23 |
| P / E | 21.5x | 20.2x | 54 | 11 |
| 1 year | 19.1% | 31.0% | 38 | 24 |
Peers (25): NVO, BMY, AZN, NVS, GSK, MRK, TEVA, JNJ, ZTS, LLY, VTRS, JAZZ, CORT, AXSM, AMRX, OGN, AMLX, TARS, SUPN, LQDA, HRMY, BHC, XERS, TRVI, GPCR. Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PFE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PFE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PFE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.